Stockreport

Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating [Seeking Alpha]

Dianthus Therapeutics, Inc.  (DNTH) 
PDF Claseprubart delivered statistically significant MG-ADL improvements in phase 2 Myasthenia Gravis and is advancing to phase 3, with topline data expected in 2H 2028. [Read more]